MSP-1014, a next generation psychedelic medicine showed superior 5-HT2A receptor efficacy and safety compared to psilocybin TORONTO, July 07, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and…


Previous articleMYND Life Sciences Provides Corporate Update
Next articleQ & A with Keeno Ahmed-Jones: Dismantling the Echo Chamber of the Psychedelic Renaissance